-
Mesothelioma Widow Defeats GE’s Request for Federal Jurisdiction of Claim
There are many reasons why mesothelioma victims prefer to have their claims heard in their local state court and why asbestos companies prefer the federal courts. State courts generally provide faster trial dates, often make it easier for victims to obtain evidence, and make it easier for them to name several asbestos companies in a
-
British Mesothelioma and Ovarian Cancer Victims File Johnson & Johnson Talc Claims
Earlier this year, attorneys in the United Kingdom indicated that mesothelioma and ovarian cancer victims were preparing to file personal injury claims against consumer giant Johnson & Johnson. This week, a group of thousands filed court documents accusing the company of knowingly and negligently selling talc that it knew was contaminated with asbestos, echoing the
-
Judge Denies Johnson & Johnson’s Request for New Mesothelioma Trial
The judge who’d overseen the case of mesothelioma victim Evan Plotkin denied Johnson & Johnson’s petition for a new trial despite the company’s arguments that the court should have precluded, in whole or part, the opinions of the plaintiff’s expert witnesses. The judge’s decision came the same week that he awarded the victim $10 million
-
United Kingdom Increases Compensation Schedule for Mesothelioma Victims
Mesothelioma victims in the United States have several options for pursuing compensation from those responsible for exposing them to asbestos, including civil lawsuits, asbestos bankruptcy trusts, and workers’ compensation. Things are handled differently in the United Kingdom: While some are able to pursue civil litigation, those whose former employers are no longer in business, and
-
Researchers Find Clue to Why Mesothelioma Tumors Fail to Respond to Immune Activity
Researchers from the Azienda Unità Sanitaria Locale-IRCCS di Reggio Emilia, in Reggio Emilia, Italy, have published the results of a recent study on why some mesothelioma patients don’t respond well to immunotherapy treatment. The scientists studied 89 mesothelioma samples and discovered that in patients whose cells showed deletion of a gene called CDKN2A, their tumors’
-
Combined Therapy Clinical Trial Seeks Mesothelioma Patients
One of medicine’s most enduring challenges is the quest for a more effective treatment for malignant mesothelioma, and Baylor College of Medicine and Duke University have built a reputation for their collaborative work in pursuit of that goal. Scientists from the esteemed institutions have recently announced another groundbreaking clinical trial that will gauge the impact
-
Mesothelioma Drug Granted Fast Track Designation
Patients diagnosed with pleural mesothelioma have limited treatment options, but the FDA’s recent approval of fast-track designation for an investigational small molecule therapeutic called VT3989 offers reason for hope. The new treatment, which is specifically designed to treat unresectable malignant pleural or nonpleural mesothelioma that has progressed after prior immune checkpoint inhibitor therapy and platinum-based chemotherapy,
-
Jury Orders Johnson & Johnson to Pay $966 Million to Mesothelioma Victim’s Family
Mae Moore was 88 years old when she died of malignant mesothelioma. The wife of a pastor, Moore had used Johnson & Johnson’s Baby Powder throughout her life and blamed asbestos in the product for her fatal illness. This week, a Los Angeles jury ordered the consumer giant to pay her family almost $1 billion
-
Pennsylvania Supreme Court to Consider Mesothelioma Victims’ Argument in Dravo Shipyard Case
Today, the Pennsylvania Supreme Court will hear arguments in a case involving mesothelioma victims and a shipyard’s parent company. The victims want to pursue asbestos exposure claims against Carmeuse Lime Inc., parent company of dissolved shipyard operator Dravo LLC, but a lower court dismissed the case based on statutory time limitations. A split appellate panel
-
Study Shows Loose-Fill Asbestos Increases Mesothelioma Risk Copy
A study conducted by researchers in Australia has highlighted the increased risk of a malignant mesothelioma diagnosis for those living in a home insulated with loose-fill asbestos insulation. Though the study was conducted in Australia, its conclusions carry great impact in both the United States and Canada, where asbestos-contaminated insulation was used in millions of
-
Mesothelioma Plaintiff’s Claim Against General Electric Moves Forward
Dennis and Susan Payne filed a mesothelioma lawsuit against General Electric after he was diagnosed with the rare, fatal form of cancer. Their claim referenced Mr. Payne’s years with the California Maritime Academy, when he worked aboard a training ship and was exposed to asbestos in a General Electric turbine. Though the company requested that
-
Honeywell Divestiture Shifts Mesothelioma Liabilities
Honeywell International announced a $1.69 billion transaction that eliminates its financial responsibility for payments to mesothelioma victims. The deal, which involved contributions from both Honeywell and corporate liability acquisition platform Delticus, permanently shifts liabilities for legacy asbestos claims that Honeywell has faced ever since it acquired North American Refractories Company (NARCO) and Bendix Friction Materials.
-
Mesothelioma Plaintiff Wins Ruling Against Talc Manufacturer
For mesothelioma patients, the path to justice is often hindered by legal complexities and roadblocks erected by asbestos companies. In the case of Craig Ludwig, talc supplier IMI Fabi LLC argued that they could not be sued in the state of New York. However, after review of the case, a New York Supreme Court judge
-
Mesothelioma Victims Challenge Court Ruling in Bestwall Bankruptcy Case
Many mesothelioma victims blame their illness on their use of products made by Georgia Pacific and its subsidiary Bestwall-Gypsum. Claims against the company have been stymied by the company’s attempts to use bankruptcy to evade liability for its negligence. Recently, claimants have asked the full Fourth Circuit Court to reconsider a ruling that allowed the
-
Libby’s CARD Clinic Continues Critical Mesothelioma Screening
Mesothelioma and other asbestos-related diseases continue to be urgent public health concerns in Libby, Montana, where the Center for Asbestos Related Disease (CARD) has provided essential clinical services since 2002. In June 2025, renowned physicians, scientists, and asbestos experts gathered in Libby for a screening, outreach, and education retreat. While there, they reaffirmed the critical
-
ADAO Celebrates 20th Annual Conference on the Eve of Mesothelioma Awareness Day
Today is Mesothelioma Awareness Day, and the Asbestos Disease Awareness Organization (ADAO) marked it by sending a letter to the U.S. Congress calling for swift passage of the bipartisan Alan Reinstein Ban Asbestos Now (ARBAN) Act of 2025. It also launched the Asbestos Action Navigator, the first mobile tool for asbestos prevention, exposure tracking, and care management. This
-
Doctor’s Long-awaited Mesothelioma Lawsuit Begins in Florida
Dr. Albert Casaretto died of pleural mesothelioma in 2022, after more than fifty years of using Johnson & Johnson’s talcum powder. His initial claim against the company and other defendants was entered in 2018, shortly after he was diagnosed with the rare and deadly disease, and scheduled for trial in 2020. Court closures due to
-
Louisiana Court Rules Against Shipyard in Mesothelioma Case
After his wife, Elaine, died from malignant mesothelioma, Joseph Raymond Steib, Sr., filed a lawsuit against Huntington Ingalls Incorporated, seeking justice and compensation for her death, which he believed was caused by asbestos exposure from his work at the Avondale Shipyards. When the company attempted to claim federal immunity protections and remove the case to
-
Boston Jury Awards $83 Million to Mesothelioma Victim
In what is believed to be the largest asbestos verdict ever awarded in the state of Massachusetts, a Boston jury has awarded a widower $83 million, including $60 million in punitive damages. Michael Lapointe’s lawsuit against American Art Clay Company accused the company’s asbestos-containing ceramics products of causing his wife, Judith’s, death, and called the
-
FDA Approval of New Solid Tumor Treatment Option Means More Choices for Mesothelioma Patients
The FDA’s recent approval of subcutaneous pembrolizumab (Keytruda Qlex) for solid tumors means that mesothelioma patients will have a more convenient treatment option available to them. Subcutaneous treatments can be administered quickly under the skin rather than through time-consuming intravenous infusions. The approval covers all types of solid tumor cancers for which intravenous pembrolizumab has
